Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Protara Therapeutics reports Q1 EPS ($1.20), consensus (73c) » 07:52
05/06/21
05/06
07:52
05/06/21
07:52
TARA

Protara Therapeutics

$10.30 /

-0.08 (-0.77%)

"We remain on track…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TARA Protara Therapeutics
$10.30 /

-0.08 (-0.77%)

TARA Protara Therapeutics
$10.30 /

-0.08 (-0.77%)

04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
TARA Protara Therapeutics
$10.30 /

-0.08 (-0.77%)

  • 22
    Sep
TARA Protara Therapeutics
$10.30 /

-0.08 (-0.77%)

Yesterday
Options
new option listings and one option delisting on May 5th » 08:30
05/05/21
05/05
08:30
05/05/21
08:30
AIQ

Alliance HealthCare

$28.51 /

-0.66 (-2.26%)

, ASEA

Aegean Sea

$14.66 /

-0.185 (-1.25%)

, BTX

Brooklyn ImmunoTherapeutics

$54.73 /

-21.32 (-28.03%)

, CIGI

Colliers International

$115.70 /

+6.09 (+5.56%)

, DOOO

BRP Inc.

$90.90 /

-1.6 (-1.73%)

, EDR

Endeavor

$29.99 /

-0.785 (-2.55%)

, ELDN

Eledon Pharmaceuticals

$9.85 /

-0.05 (-0.51%)

, FLUX

Flux Power

$10.44 /

-0.505 (-4.61%)

, FSV

FirstService

$159.97 /

-2.31 (-1.42%)

, GWRS

Global Water Resources

$16.50 /

-0.67 (-3.90%)

, MYMD

MyMD Pharmaceuticals

$4.20 /

-0.01 (-0.24%)

, NEBC

Nebula Caravel Acquisition

$9.90 /

+ (+0.00%)

, SLGL

Sol-Gel Technologies

$10.51 /

-0.19 (-1.78%)

, TARA

Protara Therapeutics

$10.43 /

-0.76 (-6.79%)

, VRCA

Verrica Pharmaceuticals

$12.27 /

-0.08 (-0.65%)

New option listings for…

New option listings for May 5th include Global X Funds Global X Future Analytics Tech ETF (AIQ), Global X SuperDividend Alternatives (ALTY), Global X Southeast Asia (ASEA), Aspirational Consumer Lifestyle Corp (Class A Stock) (ASPL), Brooklyn ImmunoTherapeutics Inc (BTX), Global X MSCI China Information Technology ETF (CHIK), Colliers International (CIGI), BRP Inc (DOOO), Endeavor Group Holdings Inc (Class A Stock) (EDR), Eledon Pharmaceuticals Inc (ELDN), Fidelity Momentum Factor ETF (FDMO), Fidelity Dividend ETF for Rising Rates (FDRR), Fidelity Core Dividend ETF (FDVV), Fidelity International High Dividend ETF (FIDI), Flux Power Holdings Inc (FLUX), Fidelity Quality Factor ETF (FQAL), Fidelity Small Mid Multifactor ETF (FSMD), FirstService (FSV), Fidelity Value Factor ETF (FVAL), Global Water Resources (GWRS), Global X Thematic Growth ETF (GXTG), Direxion Daily S&P 500 High Beta Bull 3x Shares (HIBL), Global X Conscious Companies (KRMA), Global X Millennials Thematic (MILN), MyMD Pharmaceuticals Inc (MYMD), Nebula Caravel Acquisition Corporation (Class A Stock) (NEBC), Fidelity Nasdaq Composite Index (ONEQ), First Trust Nasdaq Artificial Intelligence and Robotics (ROBT), Global X SuperDividend Emerging Markets ETF (SDEM), Sol Gel Technologies Ltd (SLGL), SVF Investment Corporation (Class A Stock) (SVFA), Protara Therapeutics Inc (TARA), Verrica Parmaceuticals Inc (VRCA), Direxion Daily Consumer Discretionary Bull 3x Shares (WANT), Direxion Daily Dow Jones Internet Bull 3x Shares (WEBL), and Global X S&P 500 Covered Call ETF (XYLD). Option delistings effective May 5th include Valaris Plc (VALPQ).

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

AIQ Alliance HealthCare
$28.51 /

-0.66 (-2.26%)

ASEA Aegean Sea
$14.66 /

-0.185 (-1.25%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

02/16/21 TD Securities
Colliers International price target raised to $125 from $100 at TD Securities
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
01/25/21
Fly Intel: Top five analyst initiations
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

04/26/21 Citi
BRP Inc. initiated with a Buy at Citi
04/06/21 Stifel
BRP Inc. downgraded to Hold from Buy at Stifel
03/29/21 Desjardins
BRP Inc. price target raised to C$131 from C$107 at Desjardins
03/26/21 CIBC
BRP Inc. price target raised to C$117 from C$100 at CIBC
EDR Endeavor
$29.99 /

-0.785 (-2.55%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/22/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
02/08/21 SVB Leerink
SVB Leerink bullish on Eledon Pharmaceuticals, initiates with an Outperform
FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21
Flux Power initiated with a Buy at Maxim
10/12/20 Roth Capital
Flux Power initiated with a Buy at Roth Capital
FSV FirstService
$159.97 /

-2.31 (-1.42%)

04/28/21 Raymond James
Raymond James downgrades FirstService to Market Perform on 'healthy valuation'
04/28/21 Raymond James
FirstService downgraded to Market Perform from Outperform at Raymond James
04/28/21
Fly Intel: Top five analyst downgrades
04/28/21 TD Securities
FirstService downgraded to Hold from Buy at TD Securities
GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

02/25/21 Roth Capital
Global Water Resources price target raised to $19 from $12.50 at Roth Capital
MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

04/09/21
Fly Intel: Top five analyst initiations
04/09/21 Tigress Financial
Nebula Caravel Acquisition initiated with a Buy at Tigress Financial
03/19/21
Fly Intel: Top five analyst initiations
03/19/21 DA Davidson
Rover initiated with a Buy at DA Davidson amid COVID-related tailwinds
SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

  • 29
    Apr
  • 23
    Mar
  • 22
    Sep
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

EDR Endeavor
$29.99 /

-0.785 (-2.55%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

Over a week ago
Recommendations
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer » 07:41
04/26/21
04/26
07:41
04/26/21
07:41
TARA

Protara Therapeutics

$12.29 /

-2.79 (-18.50%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell lowered the firm's price target on Protara Therapeutics to $32 from $43 and keeps an Outperform rating on the shares. The analyst notes Protara announced that, following FDA feedback, it will conduct an efficacy trial of TARA-002 in lymphatic malformations prior to BLA submission. Gershell appreciates the long-awaited regulatory clarity on this development program, while at the same time recognizing that the less favorable scenario has materialized. Nonetheless, the robust dataset supports optimism for success in the upcoming trial, to commence patient enrollment by early 2022 as check-the-box CMC items are completed, he contends.

ShowHide Related Items >><<
TARA Protara Therapeutics
$12.29 /

-2.79 (-18.50%)

TARA Protara Therapeutics
$12.29 /

-2.79 (-18.50%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
TARA Protara Therapeutics
$12.29 /

-2.79 (-18.50%)

  • 22
    Sep
Hot Stocks
Protara to conduct additional clinical study for TARA-002 following FDA feedback » 07:05
04/23/21
04/23
07:05
04/23/21
07:05
TARA

Protara Therapeutics

$14.99 /

+0.09 (+0.60%)

Protara Therapeutics…

Protara Therapeutics announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations, which are rare malformations of the lymphatic vasculature for which there is no U.S. Food and Drug Administration-approved treatment. Based on feedback from the FDA, the Company intends to complete confirmatory, large-scale, GMP manufacturing comparability in the second half of 2021 and subsequently initiate a clinical study in pediatric LM patients pending alignment with FDA on study design. TARA-002 is derived from the same cell bank as OK-432, a broad immunopotentiator approved in Japan and Taiwan for the treatment of LMs, where it is currently the standard of care. In 2020, Protara successfully demonstrated initial manufacturing comparability between TARA-002 and the originator compound OK-432, which has been studied in more than 500 patients in one of the largest Phase 2 trials ever conducted in LMs. TARA-002 has been granted Rare Pediatric Disease designation by the FDA for the treatment of LMs.

ShowHide Related Items >><<
TARA Protara Therapeutics
$14.99 /

+0.09 (+0.60%)

TARA Protara Therapeutics
$14.99 /

+0.09 (+0.60%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
TARA Protara Therapeutics
$14.99 /

+0.09 (+0.60%)

  • 22
    Sep
Conference/Events
Protara Therapeutics management to meet virtually with Oppenheimer » 05:55
04/22/21
04/22
05:55
04/22/21
05:55
TARA

Protara Therapeutics

$14.90 /

+0.19 (+1.29%)

Virtual Meetings to be…

Virtual Meetings to be held on April 21-22 hosted by Oppenheimer.

ShowHide Related Items >><<
TARA Protara Therapeutics
$14.90 /

+0.19 (+1.29%)

TARA Protara Therapeutics
$14.90 /

+0.19 (+1.29%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
TARA Protara Therapeutics
$14.90 /

+0.19 (+1.29%)

  • 22
    Sep
Conference/Events
Protara Therapeutics management to meet virtually with Oppenheimer » 04:55
04/21/21
04/21
04:55
04/21/21
04:55
TARA

Protara Therapeutics

$14.79 /

-0.4 (-2.63%)

Virtual Meetings to be…

Virtual Meetings to be held on April 21-22 hosted by Oppenheimer.

ShowHide Related Items >><<
TARA Protara Therapeutics
$14.79 /

-0.4 (-2.63%)

TARA Protara Therapeutics
$14.79 /

-0.4 (-2.63%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
TARA Protara Therapeutics
$14.79 /

-0.4 (-2.63%)

  • 22
    Sep
Hot Stocks
Protara Therapeutics announces appointment of Olivo as Chief Medical Officer » 08:37
04/19/21
04/19
08:37
04/19/21
08:37
TARA

Protara Therapeutics

$15.82 /

-0.22 (-1.37%)

, GILD

Gilead

$66.88 /

+1.11 (+1.69%)

Protara Therapeutics…

Protara Therapeutics (TARA) announced the appointment of Martin Olivo, M.D. as Chief Medical Officer, effective immediately. Olivo brings to Protara more than 15 years of experience in oncology translational and clinical research and global drug development, most recently serving as Vice President, Breast Cancer Clinical Development Lead at Gilead Sciences (GILD). "We are very excited to welcome Dr. Olivo to our leadership team," said Jesse Shefferman, CEO of Protara Therapeutics. "The depth of his experience supporting the development and approval of oncology drug candidates is expected to be particularly instrumental as we continue to advance our lead product candidate, TARA-002, for the treatment of non-muscle invasive bladder cancer and lymphatic malformations."

ShowHide Related Items >><<
TARA Protara Therapeutics
$15.82 /

-0.22 (-1.37%)

GILD Gilead
$66.88 /

+1.11 (+1.69%)

TARA Protara Therapeutics
$15.82 /

-0.22 (-1.37%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
GILD Gilead
$66.88 /

+1.11 (+1.69%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
TARA Protara Therapeutics
$15.82 /

-0.22 (-1.37%)

GILD Gilead
$66.88 /

+1.11 (+1.69%)

  • 22
    Sep
GILD Gilead
$66.88 /

+1.11 (+1.69%)

GILD Gilead
$66.88 /

+1.11 (+1.69%)

GILD Gilead
$66.88 /

+1.11 (+1.69%)

Conference/Events
Protara Therapeutics management to meet virtually with Oppenheimer » 15:01
04/14/21
04/14
15:01
04/14/21
15:01
TARA

Protara Therapeutics

$16.95 /

+0.27 (+1.62%)

Virtual Meetings to be…

Virtual Meetings to be held on April 21-22 hosted by Oppenheimer.

ShowHide Related Items >><<
TARA Protara Therapeutics
$16.95 /

+0.27 (+1.62%)

TARA Protara Therapeutics
$16.95 /

+0.27 (+1.62%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
TARA Protara Therapeutics
$16.95 /

+0.27 (+1.62%)

  • 22
    Sep
Over a month ago
Earnings
Protara Therapeutics reports Q4 EPS (79c), consensus (54c) » 07:32
03/11/21
03/11
07:32
03/11/21
07:32
TARA

Protara Therapeutics

$15.91 /

+0.61 (+3.99%)

"We believe 2021…

"We believe 2021 will be a transformative year for Protara, and we are entering it with strong momentum," said Jesse Shefferman, CEO of Protara Therapeutics. "We remain on track to commence a Phase 1 study of TARA-002 in patients with non-muscle invasive bladder cancer, a pressing area of unmet need, by the end of the year. We believe that TARA-002 has the opportunity to play a meaningful role in the current NMIBC treatment landscape. We are in discussions with the U.S. Food and Drug Administration's (FDA) Division of Vaccines and Related Products to establish a path forward to file our Biological License Application for TARA-002 in lymphatic malformations. We are encouraged by the progress to date and, at the FDA's request, have submitted the full Clinical Study Report of a randomized Phase 2 study of OK-432 in LMs led by the University of Iowa. We look forward to continuing our dialogue with the FDA."

ShowHide Related Items >><<
TARA Protara Therapeutics
$15.91 /

+0.61 (+3.99%)

TARA Protara Therapeutics
$15.91 /

+0.61 (+3.99%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
TARA Protara Therapeutics
$15.91 /

+0.61 (+3.99%)

  • 22
    Sep
Over a quarter ago
Hot Stocks
Protara Therapeutics reports inducement grants under Nasdaq listing rule » 08:15
02/02/21
02/02
08:15
02/02/21
08:15
TARA

Protara Therapeutics

$17.80 /

-0.18 (-1.00%)

Protara Therapeutics…

Protara Therapeutics announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,500 shares of common stock to five new employees. Each stock option has an exercise price per share equal to $17.83 per share, Protara's closing trading price on February 1, 2021, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the individual's applicable vesting commencement date and 1/36th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee's continued service relationship with Protara through the applicable vesting dates. The Compensation Committee of Protara's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with NASDAQ Listing Rule 5635(c)(4).

ShowHide Related Items >><<
TARA Protara Therapeutics
$17.80 /

-0.18 (-1.00%)

TARA Protara Therapeutics
$17.80 /

-0.18 (-1.00%)

10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
07/29/20 Guggenheim
Protara Therapeutics initiated with a Buy at Guggenheim
TARA Protara Therapeutics
$17.80 /

-0.18 (-1.00%)

  • 22
    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.